IVVD

What one share of Invivyd holds

Biological Products, (No Diagnostic Substances)

Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of monoclonal antibody (“mAb”) therapies for the prevention and treatment of serious viral infectious diseases. We are devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19.

Invivyd’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.

Per-share figures
Sales$0.22
Profit−$0.40
Capex (buildings and equipment)$0.00
Free cash flow−$0.41
Cash and investments$0.54
Book value$0.61

Per share by fiscal year

YearSalesProfitCapexFree cashDividendsBook value
2021—−$5.32$0.00−$4.34——
2022—−$2.23$0.02−$2.05—$3.26
2023$0.00−$1.81$0.01−$1.59—$1.61
2024$0.21−$1.43$0.00−$1.44—$0.56
2025$0.31−$0.30$0.00−$0.34—$0.86

Common questions about Invivyd

How much does one share of Invivyd earn?

Over the last 12 months, Invivyd lost $0.40 for each share on $0.22 of sales.

Does Invivyd pay a dividend?

Invivyd didn’t pay a dividend over the last 12 months, according to its SEC filings.

What is Invivyd’s book value per share?

Invivyd’s book value is $0.61 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.

How much cash and debt does each share of Invivyd have?

Each share of Invivyd has $0.54 of cash and investments, as of June 30, 2026.

What is Invivyd’s free cash flow per share?

−$0.41 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.

Has Invivyd bought back shares?

Invivyd’s share count rose about 304% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.

From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.